Mammalian target of rapamycin signaling and autophagy: Roles in lymphangioleiomyomatosis therapy

Proceedings of the American Thoracic Society

Volumn 7, Issue 1, 2010, Pages 48-53

  Yu, Jane ^a   Parkhitko, Andrey A ^a   Henske, Elizabeth Petri ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Chloroquine; Rapamycin; Rheb; Tuberin; Tuberous sclerosis

Indexed keywords

CHLOROQUINE; HYDROXYCHLOROQUINE; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE; TUBERIN; TUMOR SUPPRESSOR PROTEIN;

AUTOPHAGY; CELL SIZE; CELL SURVIVAL; DROSOPHILA; DRUG MECHANISM; GENE MUTATION; HUMAN; LYMPHANGIOLEIOMYOMATOSIS; NONHUMAN; REVIEW; TUBEROUS SCLEROSIS; ANGIOMYOLIPOMA; ANIMAL; CLINICAL TRIAL; DRUG EFFECT; FEMALE; GENETICS; LUNG FUNCTION TEST; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANGIOMYOLIPOMA; ANIMALS; AUTOPHAGY; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHANGIOLEIOMYOMATOSIS; PROTEIN-SERINE-THREONINE KINASES; RESPIRATORY FUNCTION TESTS; SIGNAL TRANSDUCTION; SIROLIMUS; TUBEROUS SCLEROSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 77953201300     PISSN: 15463222     EISSN: 19435665     Source Type: Journal    
DOI: 10.1513/pats.200909-104JS     Document Type: Review

References (80)

1. Johnson SR. Lymphangioleiomyomatosis. Eur Respir J 2006;27:1056-1065.
2. McCormack FX. Lymphangioleiomyomatosis: a clinical update. Chest 2008;133:507-516. (Pubitemid 351272412)
3. Taveira-DaSilva AM, Steagall WK, Moss J. Lymphangioleiomyomatosis. Cancer Control 2006;13:276-285.
4. Kuhnen C, Preisler K, Muller KM. (Pulmonary lymphangioleiomyomatosis. Morphologic and immunohistochemical findings). Pathologe 2001;22:197-204.
5. Matsumoto Y, Horiba K, Usuki J, Chu SC, Ferrans VJ, Moss J. Markers of cell proliferation and expression of melanosomal antigen in lymphangioleiomyomatosis. Am J Respir Cell Mol Biol 1999;21:327-336. (Pubitemid 129517187)
6. Zhe X, Schuger L. Combined smooth muscle and melanocytic differentiation in lymphangioleiomyomatosis. J Histochem Cytochem 2004;52:1537-1542. (Pubitemid 39603253)
7. Chilosi M, Pea M, Martignoni G, Brunelli M, Gobbo S, Poletti V, Bonetti F. Cathepsin-k expression in pulmonary lymphangioleiomyomatosis. Mod Pathol 2009;22:161-166.
8. Ferri N, Carragher NO, Raines EW. Role of discoidin domain receptors 1 and 2 in human smooth muscle cell-mediated collagen remodeling: potential implications in atherosclerosis and lymphangioleiomyomatosis. Am J Pathol 2004;164:1575-1585. (Pubitemid 38529760)
9. Hayashi T, Fleming MV, Stetler-Stevenson WG, Liotta LA, Moss J, Ferrans VJ, Travis WD. Immunohistochemical study of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in pulmonary lymphangioleiomyomatosis (LAM). Hum Pathol 1997;28:1071-1078. (Pubitemid 27388109)
10. Matsui K, Takeda K, Yu ZX, Travis WD, Moss J, Ferrans VJ. Role for activation of matrix metalloproteinases in the pathogenesis of pulmonary lymphangioleiomyomatosis. Arch Pathol Lab Med 2000;124:267-275. (Pubitemid 30090613)
11. Matsui K, Riemenschneider WK, Hilbert SL, Yu ZX, Takeda K, Travis WD, Moss J, Ferrans VJ. Hyperplasia of type II pneumocytes in pulmonary lymphangioleiomyomatosis. Arch Pathol Lab Med 2000;124:1642-1648.
12. Zhe X, Yang Y, Jakkaraju S, Schuger L. Tissue inhibitor of metalloproteinase-3 downregulation in lymphangioleiomyomatosis: potential consequence of abnormal serum response factor expression. Am J Respir Cell Mol Biol 2003;28:504-511. (Pubitemid 36399373)
13. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med 2006;355:1345-1356.
14. Franz DN, Brody A, Meyer C, Leonard J, Chuck G, Dabora S, Sethuraman G, Colby TV, Kwiatkowski DJ, McCormack FX. Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis. Am J Respir Crit Care Med 2001;164:661-668. (Pubitemid 32801674)
15. Kelly J, Moss J. Lymphangioleiomyomatosis. Am J Med Sci 2001;321:17-25.
16. Burger CD. S-LAM in men: is pulmonary function different from that seen in women? Am J Respir Crit Care Med 2008;177:356, author reply 357.
17. Fiore MG, Sanguedolce F, Lolli I, Piscitelli D, Ricco R. Abdominal lymphangioleiomyomatosis in a man with Klinefelter syndrome: the first reported case. Ann Diagn Pathol 2005;9:96-100. (Pubitemid 40460745)
18. Henske EP. Metastasis of benign tumor cells in tuberous sclerosis complex. Genes Chromosomes Cancer 2003;38:376-381. (Pubitemid 37466939)
19. Kim NR, Chung MP, Park CK, Lee KS, Han J. Pulmonary lymphangioleiomyomatosis and multiple hepatic angiomyolipomas in a man. Pathol Int 2003;53:231-235. (Pubitemid 36628231)
20. McCormack FX, Moss J. S-LAM in a man? Am J Respir Crit Care Med 2007;176:3-5.
21. Sandrini A, Krishnan A, Yates DH. S-LAM in a man: the first case report. Am J Respir Crit Care Med 2008;177:356, author reply 357.
22. Henske EP, Neumann HP, Scheithauer BW, Herbst EW, Short MP, Kwiatkowski DJ. Loss of heterozygosity in the tuberous sclerosis (TSC2) region of chromosome band 16p13 occurs in sporadic as well as TSC-associated renal angiomyolipomas. Genes Chromosomes Cancer 1995;13:295-298.
23. Strizheva GD, Carsillo T, Kruger WD, Sullivan EJ, Ryu JH, Henske EP. The spectrum of mutations in tsc1 and TSC2 in women with tuberous sclerosis and lymphangiomyomatosis. Am J Respir Crit Care Med 2001;163:253-258. (Pubitemid 32095277)
24. Carsillo T, Astrinidis A, Henske EP. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci USA 2000;97:6085-6090. (Pubitemid 30367527)
25. Yu J, Astrinidis A, Henske EP. Chromosome 16 loss of heterozygosity in tuberous sclerosis and sporadic lymphangiomyomatosis. Am J Respir Crit Care Med 2001;164:1537-1540. (Pubitemid 33124040)
26. Karbowniczek M, Astrinidis A, Balsara BR, Testa JR, Lium JH, Colby TV, McCormack FX, Henske EP. Recurrent lymphangiomyomatosis after transplantation: genetic analyses reveal a metastatic mechanism. Am J Respir Crit Care Med 2003;167:976-982. (Pubitemid 36408163)
27. Yu JJ, Robb VA, Morrison TA, Ariazi EA, Karbowniczek M, Astrinidis A, Wang C, Hernandez-Cuebas L, Seeholzer LF, Nicolas E, et al. Estrogen promotes the survival and pulmonary metastasis of tuberinnull cells. Proc Natl Acad Sci USA 2009;106:2635-2640.
28. Crooks DM, Pacheco-Rodriguez G, DeCastro RM, McCoy JP Jr, Wang JA, Kumaki F, Darling T, Moss J. Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis. Proc Natl Acad Sci USA 2004;101:17462-17467. (Pubitemid 39657427)
29. Yu J, Henske EP. MTOR activation, lymphangiogenesis, and estrogen-mediated cell survival: the "perfect storm" of pro-metastatic factors in LAM pathogenesis. Lymphat Res Biol (In press).
30. Gao X, Pan D. TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth. Genes Dev 2001;15:1383-1392. (Pubitemid 32524645)
31. Potter CJ, Huang H, Xu T. Drosophila TSC1 functions with TSC2 to antagonize insulin signaling in regulating cell growth, cell proliferation, and organ size. Cell 2001;105:357-368. (Pubitemid 32455342)
32. Tapon N, Ito N, Dickson BJ, Treisman JE, Hariharan IK. The drosophila tuberous sclerosis complex gene homologs restrict cell growth and cell proliferation. Cell 2001;105:345-355. (Pubitemid 32455341)
33. El-Hashemite N, Zhang H, Henske EP, Kwiatkowski DJ. Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma. Lancet 2003;361:1348-1349. (Pubitemid 36514870)
34. Goncharova EA, Goncharov DA, Spaits M, Noonan DJ, Talovskaya E, Eszterhas A, Krymskaya VP. Abnormal growth of smooth musclelike cells in lymphangioleiomyomatosis: role for tumor suppressor TSC2. Am J Respir Cell Mol Biol 2006;34:561-572.
35. Kenerson HL, Aicher LD, True LD, Yeung RS. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res 2002;62:5645-5650. (Pubitemid 35204715)
36. Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, Schmithorst VJ, Laor T, Brody AS, Bean J, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008;358:140-151.
37. Davies DM, Johnson SR, Tattersfield AE, Kingswood JC, Cox JA, McCartney DL, Doyle T, Elmslie F, Saggar A, de Vries PJ, et al. Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis. N Engl J Med 2008;358:200-203.
38. Choo AY, Yoon SO, Kim SG, Roux PP, Blenis J. Rapamycin differentially inhibits s6ks and 4e-bp1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci USA 2008;105:17414-17419.
39. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, Reichling LJ, Sim T, Sabatini DM, Gray NS. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 2009;284:8023-8032.
40. Thoreen CC, Sabatini DM. Rapamycin inhibits mTORC1, but not completely. Autophagy 2009;5:725-726.
41. Karbowniczek M, Cash T, Cheung M, Robertson GP, Astrinidis A, Henske EP. Regulation of B-Raf kinase activity by tuberin and Rheb is mammalian target of rapamycin (mTOR)-independent. J Biol Chem 2004;279:29930-29937. (Pubitemid 38937912)
42. Huang J, Dibble CC, Matsuzaki M, Manning BD. The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol Cell Biol 2008;28:4104-4115. (Pubitemid 351812994)
43. Karbowniczek M, Robertson GP, Henske EP. Rheb inhibits C-Raf activity and B-Raf/C-Raf heterodimerization. J Biol Chem 2006;281:25447-25456. (Pubitemid 44401933)
44. Lee PS, Tsang SW, Moses MA, Trayes-Gibson Z, Hsiao LL, Jensen R, Squillace R, Kwiatkowski DJ. Rapamycin-insensitive up-regulation of MMP2 and other genes in tuberous sclerosis complex 2-deficient lymphangioleiomyomatosis- like cells. Am J Respir Cell Mol Biol 2010;42:227-234.
45. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008;132:27-42.
46. Hippert MM, O'Toole PS, Thorburn A. Autophagy in cancer: good, bad, or both? Cancer Res 2006;66:9349-9351.
47. Levine B, Yuan J. Autophagy in cell death: an innocent convict? J Clin Invest 2005;115:2679-2688.
48. Mijaljica D, Prescott M, Devenish RJ. Different fates of mitochondria: alternative ways for degradation? Autophagy 2007;3:4-9.
49. Amaravadi RK, Yu D, Lum JJ, Bui T, Christophorou MA, Evan GI, Thomas-Tikhonenko A, Thompson CB. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest 2007;117:326-336. (Pubitemid 46203961)
50. Backer JM. The regulation and function of class III PI3Ks: novel roles for vps34. Biochem J 2008;410:1-17. (Pubitemid 351300321)
51. Inoki K, Li Y, Xu T, Guan KL. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 2003;17:1829-1834. (Pubitemid 36944560)
52. Kondo Y, Kanzawa T, Sawaya R, Kondo S. The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 2005;5:726-734. (Pubitemid 41486365)
53. Bellot G, Garcia-Medina R, Gounon P, Chiche J, Roux D, Pouyssegur J, Mazure NM. Hypoxia-induced autophagy is mediated through hypoxia-inducible factor induction of bnip3 and bnip3l via their bh3 domains. Mol Cell Biol 2009;29:2570-2581.
54. Nicklin P, Bergman P, Zhang B, Triantafellow E, Wang H, Nyfeler B, Yang H, Hild M, Kung C, Wilson C, et al. Bidirectional transport of amino acids regulates mTOR and autophagy. Cell 2009;136:521-534.
55. Ganley IG, Lam du H, Wang J, Ding X, Chen S, Jiang X. ULK1.ATG13.FIP200 complex mediates mtor signaling and is essential for autophagy. J Biol Chem 2009;284:12297-12305.
56. Noda T, Ohsumi Y. TOR, a phosphatidylinositol kinase homologue, controls autophagy in yeast. J Biol Chem 1998;273:3963-3966. (Pubitemid 28103257)
57. Kamada Y, Funakoshi T, Shintani T, Nagano K, Ohsumi M, Ohsumi Y. TOR-mediated induction of autophagy via an apg1 protein kinase complex. J Cell Biol 2000;150:1507-1513.
58. Klionsky DJ, Cregg JM, Dunn WA Jr, Emr SD, Sakai Y, Sandoval IV, Sibirny A, Subramani S, Thumm M, Veenhuis M, et al. A unified nomenclature for yeast autophagy-related genes. Dev Cell 2003;5:539-545. (Pubitemid 37243044)
59. Hosokawa N, Hara T, Kaizuka T, Kishi C, Takamura A, Miura Y, Iemura S, Natsume T, Takehana K, Yamada N, et al. Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex required for autophagy. Mol Biol Cell 2009;20:1981-1991.
60. Jung CH, Jun CB, Ro SH, Kim YM, Otto NM, Cao J, Kundu M, Kim DH. ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery. Mol Biol Cell 2009;20:1992-2003.
61. Crighton D, Wilkinson S, O'Prey J, Syed N, Smith P, Harrison PR, Gasco M, Garrone O, Crook T, Ryan KM. DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell 2006;126:121-134. (Pubitemid 44040988)
62. Pattingre S, Tassa A, Qu X, Garuti R, Liang XH, Mizushima N, Packer M, Schneider MD, Levine B. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 2005;122:927-939. (Pubitemid 41345209)
63. Shintani T, Klionsky DJ. Autophagy in health and disease: a double-edged sword. Science 2004;306:990-995. (Pubitemid 39482894)
64. Qu X, Yu J, Bhagat G, Furuya N, Hibshoosh H, Troxel A, Rosen J, Eskelinen EL, Mizushima N, Ohsumi Y, et al. Promotion of tumorigenesis by heterozygous disruption of the Beclin 1 autophagy gene. J Clin Invest 2003;112:1809-1820. (Pubitemid 38063704)
65. Yue Z, Jin S, Yang C, Levine AJ, Heintz N. Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc Natl Acad Sci USA 2003;100:15077-15082. (Pubitemid 37518019)
66. Liang XH, Jackson S, Seaman M, Brown K, Kempkes B, Hibshoosh H, Levine B. Induction of autophagy and inhibition of tumorigenesis by Beclin 1. Nature 1999;402:672-676. (Pubitemid 129516338)
67. Takahashi Y, Coppola D, Matsushita N, Cualing HD, Sun M, Sato Y, Liang C, Jung JU, Cheng JQ, Mule JJ, et al. Bif-1 interacts with Beclin 1 through UVRAG and regulates autophagy and tumorigenesis. Nat Cell Biol 2007;9:1142-1151. (Pubitemid 47500490)
68. Kim I, Rodriguez-Enriquez S, Lemasters JJ. Selective degradation of mitochondria by mitophagy. Arch Biochem Biophys 2007;462:245-253. (Pubitemid 46876640)
69. Karantza-Wadsworth V, Patel S, Kravchuk O, Chen G, Mathew R, Jin S, White E. Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis. Genes Dev 2007;21:1621-1635.
70. Mathew R, Kongara S, Beaudoin B, Karp CM, Bray K, Degenhardt K, Chen G, Jin S, White E. Autophagy suppresses tumor progression by limiting chromosomal instability. Genes Dev 2007;21:1367-1381. (Pubitemid 46871040)
71. Mathew R, Karp CM, Beaudoin B, Vuong N, Chen G, Chen HY, Bray K, Reddy A, Bhanot G, Gelinas C, et al. Autophagy suppresses tumorigenesis through elimination of p62. Cell 2009;137:1062-1075.
72. Koneri K, Goi T, Hirono Y, Katayama K, Yamaguchi A. Beclin 1 gene inhibits tumor growth in colon cancer cell lines. Anticancer Res 2007;27:1453-1457. (Pubitemid 46807222)
73. Mathew R, Karantza-Wadsworth V, White E. Role of autophagy in cancer. Nat Rev Cancer 2007;7:961-967.
74. Zhou X, Ikenoue T, Chen X, Li L, Inoki K, Guan KL. Rheb controls misfolded protein metabolism by inhibiting aggresome formation and autophagy. Proc Natl Acad Sci USA 2009;106:8923-8928.
75. Finlay GA, York B, Karas RH, Fanburg BL, Zhang H, Kwiatkowski DJ, Noonan DJ. Estrogen-induced smooth muscle cell growth is regulated by tuberin and associated with altered activation of platelet-derived growth factor receptor-beta and erk-1/2. J Biol Chem 2004;279:23114-23122. (Pubitemid 38685616)
76. Degenhardt K, Mathew R, Beaudoin B, Bray K, Anderson D, Chen G, Mukherjee C, Shi Y, Gelinas C, Fan Y, et al. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell 2006;10:51-64.
77. Manning BD, Logsdon MN, Lipovsky AI, Abbott D, Kwiatkowski DJ, Cantley LC. Feedback inhibition of Akt signaling limits the growth of tumors lacking TSC2. Genes Dev 2005;19:1773-1778. (Pubitemid 41126916)
78. Shah OJ, Wang Z, Hunter T. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol 2004;14:1650-1656. (Pubitemid 39239362)
79. Zhang H, Bajraszewski N, Wu E, Wang H, Moseman AP, Dabora SL, Griffin JD, Kwiatkowski DJ. PDGFRS are critical for PI3K/Akt activation and negatively regulated by mTOR. J Clin Invest 2007;117:730-738. (Pubitemid 46348531)
80. Zhang HH, Lipovsky AI, Dibble CC, Sahin M, Manning BD. S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt. Mol Cell 2006;24:185-197.